<DOC>
	<DOCNO>NCT01342601</DOCNO>
	<brief_summary>Ectoin act membrane form Ectoin-Hydro-Complex therewith provide protection external agent like aeroallergens . The effect Ectoin contain nasal spray eye drop already demonstrate several study adult Seasonal Allergic Rhinitis ( SAR ) patient show effectively reduce symptom allergic rhinitis without result significant adverse event . The aim clinical investigation demonstrate safety , tolerability efficacy Ectoin Nasal Spray Ectoin Eye Drops pediatric adolescent SAR patient . It assume Ectoin contain product show excellent safety profile good tolerability together potent efficacy treatment SAR .</brief_summary>
	<brief_title>Safety Efficacy Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops Treatment Seasonal Allergic Rhinitis ( SAR ) Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Children age 517 year diagnose seasonal allergic rhinitis general good health condition SAR , free concomitant condition treatment could interfere clinical investigation conduct , influence interpretation clinical investigation observations/results , put patient increase risk clinical investigation Sum Total Nasal Score ( TNSS ) ≥ 6 Sum Total Ocular Score ( TOSS ) ≥ 4 Confirmed diagnosis acute chronic rhinosinusitis , determine investigator History physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation , recent nasal biopsy , nasal trauma surgery , atrophic rhinitis , rhinitis medicamentosa ( within last 60 day prior screen visit ) Chronic intermittent use intranasal , oral , intramuscular , intravenous ophthalmic corticosteroid Ocular disorder allergic conjunctivitis , except hyperopia myopia strabismus Upper low airway respiratory infection disorder [ include , limited bronchitis , pneumonia , chronic sinusitis , influenza , severe acute respiratory syndrome ( SARS ) ] within 4 week prior clinical investigation start development respiratory infection runin period Start specific immunotherapy within 1 month precede enrolment clinical investigation change dose immunotherapy throughout trial Chronic moderate severe asthma accord GINA criterion treat inhaled corticosteroid ( ICS ) additional antiasthmatic treatment . Patients mild coseasonal asthma must change dose regimen ICS within 4 week prior enrolment clinical investigation clinical investigation Other respiratory disease ( e.g . Chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , alpha1Antitrypsin deficiency , sarcoidosis , bronchiectasis , allergic alveolitis , tuberculosis , emphysema , etc . ) investigator discretion</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>